The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.
This report provides:
Download Report Overview
SCOPE AND FORMAT
This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.
The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons. The biologic drug classes discussed in this report with special focus on cancer treatment are:
The following approaches to cancer therapeutics are excluded in the report:
Biological therapies for treatment of other diseases will not be addressed in this report.
The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of pre-clinical, alliance management, discovery and technology development, and marketing experience. Her primary focus areas include oncology and cardiovascular diseases, along with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She also has experience working with early start-up companies.
BIO048B - April 2010